Lastly, to validate the clinical relevance of our preclinical findings regarding exarafenib’s anti-tumor activity, we examined the clinical outcomes of patients with advanced BRAF-mutant lung cancer treated with exarafenib in the ongoing phase I/Ib clinical trial, KN-8701 (NCT04913285). This evidence concerns the gene BRAF and lung carcinoma.